Skip to main content

Outlook Therapeutics, Inc. (OTLK) Stock

Outlook Therapeutics, Inc. Stock Details, Movements and Public Alerts

Stock Details

Outlook Therapeutics, Inc. (OTLK), a prominent company in the healthcare sector within the biotechnology industry, is based in United States and primarily trades on the NCM.Currently, the stock is trading at $0.47. Over the past 52 weeks, it has ranged between $0.16 and $2.54. This places the current price at 18.5% of its 52-week high and 191.9% above its 52-week low. Recent trading volume was recorded at 4,794,517. The 14-day Relative Strength Index (RSI) stands at 36.01, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $0.60 by 21.67%. Similarly, it is below its 200-day moving average of $0.66 by 28.79%. The MACD histogram is 0.00, indicating neutral momentum (MACD Line: -0.04, Signal Line: -0.04). There is currently 1 active alert set for OTLK by users.

52-Week Range

$2.54 - $0.16

-81.48% from high · +191.93% from low

Avg Daily Volume

3,978,619

20-day average

100-day avg: 12,545,342

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

-3.90

EV/EBITDA

-2.19

EPS (TTM)

-$0.70

Price to Sales

-97.95

Beta

0.67

Less volatile than market

Q:How is OTLK valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is OTLK's risk profile compared to the market?
With a beta of 0.67, Outlook Therapeutics, Inc. is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability.

Performance & Growth

Profit Margin

0.00%

Operating Margin

-124255.27%

EBITDA

$-55,531,736

Return on Assets

-143.17%

Revenue Growth (YoY)

-99.40%

Q:How profitable and efficient is OTLK's business model?
0 The operating margin of -124255.27% reveals how efficiently the company runs its core business operations before interest and taxes.
Q:What are OTLK's recent growth trends?
Outlook Therapeutics, Inc.'s revenue declined by 99.40% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions. These growth metrics should be evaluated against Biotechnology industry averages for proper context.

Company Size & Market

Market Cap

$114.0M

Revenue (TTM)

$-1,163,481

Revenue/Share (TTM)

-$0.01

Shares Outstanding

243.45M

Book Value/Share

-$0.06

Asset Type

EQUITY

Q:What is OTLK's market capitalization and position?
Outlook Therapeutics, Inc. has a market capitalization of $114.0M, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 243.45M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.
Q:How does OTLK's price compare to its book value?
Outlook Therapeutics, Inc.'s book value per share is -$0.06, while the current stock price is $0.47, resulting in a price-to-book (P/B) ratio of -8.39. Trading below book value can indicate the market perceives challenges ahead, or it might represent a value opportunity if the assets are quality and earnings can recover. Value investors often screen for P/B ratios below 1.0. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$5.03

969.15% upside potential

Analyst Recommendations

Strong Buy

0

Buy

2

Hold

1

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for OTLK?
3 analysts cover OTLK with 67% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $5.03 implies 969.1% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on OTLK?
Current analyst recommendations:02 Buy, 1 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Oct 31, 2026, 02:17 AM

Technical Indicators

RSI (14-day)

36.01

Neutral

50-Day Moving Average

$0.60

-21.67% below MA-50

200-Day Moving Average

$0.66

-28.79% below MA-200

MACD Line

-0.04

MACD Signal

-0.04

MACD Histogram

N/A

Neutral

Q:What does OTLK's RSI value tell investors?
The RSI (Relative Strength Index) for OTLK is currently 36.01, indicating the stock is showing bearish momentum (30-40 range). Selling pressure is evident but not extreme. This often occurs during pullbacks in uptrends or early stages of downtrends. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
Q:How should traders interpret OTLK's MACD and moving average crossovers?
MACD analysis shows the MACD line at -0.04 below the signal line at -0.04, with histogram at 0.00. This bearish crossover indicates downward pressure. The narrow histogram suggests a potential trend change ahead. The 50-day MA ($0.60) is below the 200-day MA ($0.66), forming a death cross pattern that often warns of extended weakness. Price is currently below both MAs, confirming weakness.

Indicators last updated: Oct 31, 2026, 01:03 AM

Active Alerts

Alert Condition
MA Breakout (Bullish)
Threshold
50 days
Created
Oct 26, 2026, 04:14 PM

Stay Ahead of the Market with Outlook Therapeutics, Inc. Alerts

Set up price alerts for Outlook Therapeutics, Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.